Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Holding KYMR?
Track your performance easily
KYMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.60 - $50.19
Previous Close$47.3
Volume342.52K
Average Volume (3M)568.74K
Market Cap
$3.02B
Enterprise Value$2.59B
Total Cash (Recent Filing)$509.95M
Total Debt (Recent Filing)$88.18M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Nov 07, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding61,753,243
10 Day Avg. Volume300,344
30 Day Avg. Volume568,742
Standard Deviation0.25
R-Squared0.19
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)4.26
Price to Sales (P/S)33.81
Price to Cash Flow (P/CF)-16.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.29
Enterprise Value/Gross Profit33.00
Enterprise Value/Ebitda-17.01
Forecast
1Y Price Target
$51.40Price Target Upside10.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Kymera Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentKymera significantly outpaces peers at creating degraders, having brought 4 degraders into the clinic over 4 years and 2 more within the next 9 months.
Market OpportunityKT-621’s preclinical data package is encouraging, and the commercial opportunity is in the double-digit billions even with conservative assumptions.
Pipeline ProgressKymera's recent update highlighted strong pipeline progress, particularly for the I&I pipeline.
Bears Say
Clinical TrialsThe expansion will push the data readout beyond the first half of 2025.
Drug EfficacySentiment on KT-474's efficacy profile may become more negative if it seems like the current doses only have modest activity or need to be lowered due to adverse effects.
ValuationShares look more or less fully valued at these levels and remain on the sidelines.
---
Ownership Overview
Currently, No data available
---
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $9.60 and its highest was $50.19 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Currently, no data Available
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Aug 07, 2024. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.681 by $0.101.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -$0.84.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 63,755,554 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.681. Following the earnings report the stock price went down -2.68%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Among the largest hedge funds holding Kymera Therapeutics’s share is Baker Bros Advisors LP. It holds Kymera Therapeutics’s shares valued at 179M.
---
Kymera Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.40 (10.68% Upside)
$51.40 (10.68% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 223.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.4 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.29%
12-Months-Change
Fundamentals
Return on Equity
-28.18%
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
---
KYMR Earnings Call
Q2 2024
0:00 / 0:00
---
KYMR Stock 12 Month Forecast
Average Price Target
$51.40
▲(10.68% Upside)
Technical Analysis
C4 Therapeutics
―
RAPT Therapeutics
―
Blueprint Medicines
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+73.61%
assigned a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +73.61% per trade.
---